Search results

705 results

Sorted by Date . Sort by Relevance

  1. Further research is recommended to assess the effect of test-guided preventive care (see section 5.1) on clinical outcomes (such as length of stay in hospital, mortality and need for renal replacement therapy and progression to chronic kidney disease). Research should be done in children, young people and adults, but specific considerations may be needed for children and young people when care differs from that for an adult population. Studies should investigate the effects of both positive and negative test results on clinical decisions and subsequent care.

    Recommendation ID DG39/2 Question Further research is recommended to assess the effect of test-guided preventive care (see section 5.1)

  2. Companies should specify patient populations in the NHS who could benefit from test-guided preventive care for acute kidney injury. Further research is then recommended in these populations to assess the clinical effectiveness of defined care bundles designed to prevent or reduce the effect of acute kidney injury in the NHS. Research should be done in children, young people and adults, but specific considerations may be needed for children and young people when care differs from that for an adult population (see  section 4.11 ).

    Recommendation ID DG39/1 Question Companies should specify patient populations in the NHS who could benefit from test-guided preventive

  3. Evidence on the safety and efficacy of artificial iris implant insertion for acquired aniridia is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research.  Find out  what special arrangements mean on the NICE website .

    Recommendation ID IPG674 Question Evidence on the safety and efficacy of artificial iris implant insertion for acquired aniridia is limited

  4. 1.1 Evidence on the safety of electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease shows no major safety concerns. For people who are having an acute exacerbation of their chronic condition and are unable to exercise, evidence of efficacy is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit.   Find out  what standard arrangements mean on the NICE website . For people who are able to exercise, evidence on efficacy is inadequate in quality. Therefore, this procedure should only be used in the context of research. Find out  what only in research means on the NICE website .

    Recommendation ID IPG677 Question 1.1 Evidence on the safety of electrical stimulation to improve muscle strength in chronic respiratory

  5. Evidence on the safety of transcranial magnetic stimulation for obsessive-compulsive disorder raises no major safety concerns. However, evidence on its efficacy is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research.  Find out  what only in research means on the NICE website .

    Recommendation ID IPG676 Question Evidence on the safety of transcranial magnetic stimulation for obsessive-compulsive disorder raises

  6. Do the direct anterior, direct superior and supercapsular percutaneously assisted (SuperPATH) approaches to hip replacement improve patient-recorded outcome measures and reduce length of hospital stays, revision rates, neurological complications and surgical site infections compared with the posterior and anterolateral approaches?

    Recommendation ID NG157/11 Question Do the direct anterior, direct superior and supercapsular percutaneously assisted (SuperPATH) approaches

  7. Current evidence on the safety of percutaneous mechanical thrombectomy for acute deep vein thrombosis (DVT) of the leg shows there are well-recognised but infrequent complications. For acute iliofemoral DVT the evidence on efficacy is limited in quality and quantity, therefore this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    Recommendation ID IPG651/1 Question Current evidence on the safety of percutaneous mechanical thrombectomy for acute deep vein thrombosis

  8. The percentage of patients with one or more of the following conditions: CHD, atrial fibrillation, chronic heart failure, stroke or TIA, diabetes or dementia with a FAST score of ≥3 or AUDIT-C score of ≥5 in the preceding 2 years who have received brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded

    The percentage of patients with one or more of the following conditions: CHD, atrial fibrillation, chronic heart failure, stroke or TIA, diabetes or...

  9. The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses aged 25-84 (excluding those with pre-existing CHD, diabetes, stroke and/or TIA) who have had a CVD risk assessment performed in the preceding 12 months (using an assessment tool agreed with NHS England)

    The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses aged 25-84 (excluding those with pre-existing CHD,...

  10. The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses with a FAST score of ≥3 or AUDIT-C score of ≥5 in the preceding 12 months who have received a brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded.

    The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses with a FAST score of ≥3 or AUDIT-C score of ≥5 in the...

  11. In those patients with a new diagnosis of depression and assessment of severity recorded between the preceding 1 April to 31 March, the percentage of patients who have had a further assessment of severity 2–12 weeks (inclusive) after the initial recording of the assessment of severity. Both assessments should be completed using an assessment tool validated for use in primary care

    NICE indicators. NM11 depression guidance.